Weight loss medications should not be a stand-alone treatment but a part of comprehensive obesity care, also focusing on nutrition, physical activity, and mental health
A common simple protocol used in long-term laboratory studies is 3 mg of GHK-Cu per day ongoing, administered subcutaneously once daily on a continuous basis with weekends off
These can include copayments, deductibles, and coinsurance
You should avoid it if: Patients with a history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN-2), due to the potential risk of thyroid tumors
Two supporting paths readers often review next People comparing future medication access with current day-to-day support often want to look at telehealth follow-up options and broader metabolic evaluation through micronutrient testing, especially when adherence, energy, and long-term routine matter as much as the drug itself